CompletedNot Applicable

A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Caelyx (Study P05020)

154 participantsStarted 2007-10

Plain-language summary

The objective of this trial is to study the management of PPE in participants with metastatic ovarian or breast cancer treated with Caelyx, and determine the frequency of use of pharmacological treatment (preventive or therapeutic) for PPE and compliance of educational recommendations for PPE.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Women 18 years of age or older. * Participants with metastatic breast or ovarian cancer who are receiving treatment with pegylated liposomal doxorubicin. * Participants who have given their written consent. Exclusion Criteria: * Participants who are currently participating in a clinical trial.

What they're measuring

Number of Participants Who Received Concomitant Treatment Strategies to Manage Palmar-Plantar Erythrodysesthesia (PPE)

Timeframe: Participants will do a single visit, but cases will be collected during a period of 12 months.

Number of Participants That Received Curative Treatment and/or Prophylaxis Treatment for PPE

Timeframe: Participants will do a single visit, but cases will be collected during a period of 12 months.

Trial details

NCT IDNCT00746694

SponsorMerck Sharp & Dohme LLC

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2009-06

Results submitted2010-12-21

View on ClinicalTrials.gov More Ovarian Neoplasms trials